The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

The "sledgehammer-like treatment" of stem cell transplants had no benefit for most mantle cell lymphoma patients, according ...

He further explained he was diagnosed with a slow-growing "bone marrow cancer" called Waldenström's macroglobulinemia (WM): ...

SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.

The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with ...

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of ...

Genentech, a member of the Roche Group (RHHBY), announced that new and updated data from its CD20xCD3 T-cell-engaging bispecific ...